Literature DB >> 16597201

Treatment options for visceral leishmaniasis.

Margriet den Boer1, Robert N Davidson.   

Abstract

This review summarizes the current developments in therapy for visceral leishmaniasis. With the recent introduction of new drugs, the main limits in reducing deaths from visceral leishmaniasis are difficulty in diagnosis in the field and health inequality--patients lack of access to treatment. No new drugs are currently in the early stages of development. There are good reasons for the use of combination therapy; to prevent further development of resistance against the limited therapeutic options available.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16597201     DOI: 10.1586/14787210.4.2.187

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  22 in total

1.  Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani.

Authors:  Dhiraj Kumar; Ruchi Singh; Vasundhra Bhandari; Arpita Kulshrestha; Narendra Singh Negi; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-07       Impact factor: 2.289

Review 2.  A brief history of antibiotics and select advances in their synthesis.

Authors:  Kyriacos C Nicolaou; Stephan Rigol
Journal:  J Antibiot (Tokyo)       Date:  2017-07-05       Impact factor: 2.649

Review 3.  Artemisinin and its derivatives in treating protozoan infections beyond malaria.

Authors:  Cecilia Shi Ni Loo; Nelson Siu Kei Lam; Deying Yu; Xin-Zhuan Su; Fangli Lu
Journal:  Pharmacol Res       Date:  2016-11-17       Impact factor: 7.658

4.  Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine.

Authors:  Arpita Kulshrestha; Ruchi Singh; Dhiraj Kumar; Narender Singh Negi; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

5.  The midgut transcriptome of Lutzomyia longipalpis: comparative analysis of cDNA libraries from sugar-fed, blood-fed, post-digested and Leishmania infantum chagasi-infected sand flies.

Authors:  Ryan C Jochim; Clarissa R Teixeira; Andre Laughinghouse; Jianbing Mu; Fabiano Oliveira; Regis B Gomes; Dia-Eldin Elnaiem; Jesus G Valenzuela
Journal:  BMC Genomics       Date:  2008-01-14       Impact factor: 3.969

Review 6.  Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease.

Authors:  Marleen Boelaert; Kristien Verdonck; Joris Menten; Temmy Sunyoto; Johan van Griensven; Francois Chappuis; Suman Rijal
Journal:  Cochrane Database Syst Rev       Date:  2014-06-20

Review 7.  Inhibitors of RNA editing as potential chemotherapeutics against trypanosomatid pathogens.

Authors:  Reza Salavati; Houtan Moshiri; Smriti Kala; Hamed Shateri Najafabadi
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2011-11-13       Impact factor: 4.077

Review 8.  Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison.

Authors:  Gláucia F Cota; Marcos R de Sousa; Tatiani Oliveira Fereguetti; Ana Rabello
Journal:  PLoS Negl Trop Dis       Date:  2013-05-02

Review 9.  Renal involvement in leishmaniasis: a review of the literature.

Authors:  Anna Clementi; Giorgio Battaglia; Matteo Floris; Pietro Castellino; Claudio Ronco; Dinna N Cruz
Journal:  NDT Plus       Date:  2011-03-21

Review 10.  Neglected tropical diseases: survey and geometry of randomised evidence.

Authors:  Shanthi Kappagoda; John P A Ioannidis
Journal:  BMJ       Date:  2012-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.